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Abstract 
The efficacy and safety of OnabotulinumtoxinA 155-195 U (BOTOX®) in adults with chronic migraine (CM) were dem-
onstrated in both the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) studies. However, data 
about its long-term efficacy and safety in clinical settings are scanty. Therefore, the objective of this study is to evalu-
ate OnabotulinumtoxinA 155 U treatment in patients affected with CM and co-morbid medication overuse headache 
(MOH) over 2-year analysis. We prospectively evaluated 155 CM and MOH affected patients started on Onabotulinum-
toxinA 155U (PREEMPT injection paradigm) between October 2010 and November 2011 and followed-up for 2 years. 
All patients failed to positively respond to previous multiple preventive therapies that were withdrawn before starting 
OnabotulinumtoxinA. Headache days, migraine days, acute pain medication intake days and Headache Impact Test 
(HIT)-6 score were used as efficacy measures, whereas safety was evaluated with side effects occurrence during 
the treatment phase. Baseline data were collected from patients headache diary referred to the previous month, 
and patients were evaluated every 3 months at the time of each injection. OnabotulinumtoxinA 155U significantly 
reduced the number of headache and migraine days (p < 0.001), acute pain medication intake days (p < 0.001) and 
HIT-6 score (p < 0.001) when compared with the baseline data. The reduction was significant after the first injection 
(p < 0.001), and gradually increased during the 2 years of treatment. Treatment related adverse events were transient 
and mild-moderate (e.g. headache, injection-site pain, eyelid ptosis, musculoskeletal weakness). This prospective 
2-years analysis of efficacy and safety of long-term treatment with OnabotulinumtoxinA 155 U in patients affected 
with CM and MOH confirms the efficacy data from previous Randomized Clinical Trials for CM prophylaxis. Moreover, 
here we demonstrate that OnabotulinumtoxinA can be safely used for the long-term treatment of MOH comorbidity 
in CM.
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Background
Migraine is the most frequent neurological disease 
observed in clinical practice. It is a primary headache dis-
order associated with an important socioeconomic bur-
den (Steiner et al. 2011; Bloudek et al. 2012).
According to the results of the Global Burden of Dis-
ease Study 2013, headache disorders are the third cause 
of disability worldwide when considering the years of life 
lost because of disability, and migraine alone is ranked at 
the 6th place (GBDS 2015; Steiner et al. 2015).
Migraine can be episodic or chronic, depending on 
the frequency of the headache attacks. Compared to 
episodic migraine, Chronic Migraine (CM) is associated 
with higher disability, lower quality of life and greater 
health resource utilization. In fact, patients affected with 
CM often use multiple medications, both in prophylac-
tic and in the acute treatment. Moreover, the excessive 
use of acute pain medications might increase the risk of 
medication overuse headache (MOH). CM has also been 
Open Access
*Correspondence:  andrea.negro@uniroma1.it 
6 Molecular Medicine Department, Sant’Andrea Hospital, Sapienza 
University, Via di Grottarossa 1035-1039, Rome, Italy
Full list of author information is available at the end of the article
Page 2 of 8Negro et al. SpringerPlus  (2015) 4:826 
demonstrated to be an independent risk factor for car-
diovascular disorders and ischemic stroke, and higher 
frequency of attacks might lead to a chronic intake of 
non-steroidal anti-inflammatory drugs (NSAIDs) and 
triptans, both associated with a greater likelihood of 
developing cardiovascular events (Tana et  al. 2013). 
Therefore chronic migraine prevention and reduction of 
the attacks frequency might also be essential for the car-
diovascular risk reduction.
The available drugs for the preventive treatment of CM 
belong to different classes (i.e. anti-epileptic, antidepres-
sants, beta-blockers, calcium channel antagonists) and 
are generally used in mono-therapy. In fact, evidence 
about the preventive efficacy of drugs combinations is not 
sufficiently strong, and the efficacy of each single medica-
tion should be carefully evaluated alone. Moreover, the 
very frequent presence of comorbidities should drive the 
choice of a preventive migraine treatment, in order to 
reduce the patient’s medication intake and increase the 
clinical efficacy for both the disorders (Negro et al. 2010). 
Anyway, the response to a specific preventive drug is 
variable for each patient and not always predictable and 
fluctuates over time.
In 2010 the efficacy and safety of Onabotulinum-
toxinA were evaluated in the prophylactic treatment 
of CM with a Randomized Clinical Trial, namely the 
“Phase III Research Evaluating Migraine Prophylaxis 
Therapy” (PREEMPT) clinical program. This consisted 
in two phases 3, multicenter double-blind, parallel-
group, placebo-controlled studies (PREEMPT 1 and 
2) (Aurora et  al. 2010; Diener et  al. 2010; Dodick et  al. 
2010). PREEMPT enrolled 1384 adult patients with CM 
in North America and Europe, which went through a 
24-week randomized, double-blind, parallel-group, pla-
cebo-controlled phase followed by a 32-week open-label 
phase, with injections repeated every 12  weeks of 155-
195 U of OnabotulinumtoxinA.
Our experience with OnabotulinumtoxinA for the pre-
vention of chronic daily headaches started in 2001. At 
that time we administered injections of Onabotulinum-
toxinA 100 U with an off-label use (Farinelli et al. 2006). 
The dose was later increased to 155 U in 2010 after the 
publication of the PREEMPT studies.
Since 2010, we administered OnabotulinumtoxinA 
155 U injections in 31 sites every 3 months following the 
PREEMPT injection paradigm, without the administra-
tion of the additional 40 U.
In our Headache Clinic the preventive treatment 
with OnabotulinumtoxinA was offered to all the adults 
patients that were affected with CM with or without 
medication overuse (diagnosis made according with 
the IHS criteria 2004 revised in 2006) (Headache Clas-
sification Subcommittee 2004; Headache Classification 
Committee 2006). We offered such treatment only to 
patients with contraindications or lack of efficacy or 
tolerability to other preventive drugs (beta-blockers, 
calcium channel blockers, antiepileptics and antidepres-
sants). We did not offer OnabotulinumtoxinA treatment 
to patients with co-morbid neuromuscular disorders, 
psychiatric diseases considered incompatible with such 
kind of treatment, pregnancy and breast-feeding.
OnabotulinumtoxinA was not approved by the Italian 
regulatory drug agency (AIFA) for the prevention of CM, 
therefore at that time we used it off-label and all patients 
had to give an explicit informed consent. All patients 
with criteria for MOH underwent withdrawal and detoxi-
fication therapeutic regimen before starting Onabotuli-
numtoxinA. A program of at least 3 cycles of injections 
was planned for every patient. At the time of the fourth 
injection the clinical response was evaluated and if there 
was a response (reduction ≥50  % of migraine days) the 
patient could continue the treatment, otherwise Onabot-
ulinumtoxinA injections were discontinued.
With the except of the PREEEMPT studies, large and 
long term studies on OnabotulinumtoxinA efficacy and 
safety have not been published. Given our extensive clini-
cal experience with OnabotulinumtoxinA, the aim of this 
study was to prospectively evaluate its long-term efficacy 
and safety in the treatment of CM and co-morbid MOH 
over 2-year period.
Methods
The protocol was reviewed and approved by the Ethical 
Committee of Sant’Andrea Hospital, Sapienza University 
of Rome. Each patient gave a free, informed consent for 
the participation in the study and the analysis and publi-
cation of the protocol data.
We included in the study all the patients affected with 
CM with MOH that referred to our Headache Clinic 
between October 2010 and November 2011. We included 
only patients with criteria for MOH who had failed one 
or more withdrawal attempts, and all the CM patients 
who had received and failed other preventive therapies 
due to lack of efficacy or intolerable side effects. Any 
patient was allowed to take preventive oral medication 
during treatment with OnabotulinumtoxinA.
OnabotulinumtoxinA was administered in a Day Hos-
pital setting and was properly charged to our National 
Health System. It was injected every 3 months (±1 week) 
following the PREEMPT injection paradigm: all patients 
received a dose of 155 U of OnabotulinumtoxinA admin-
istered to 31 injection sites across seven head and neck 
muscles using a “fixed-site, fixed-dose” injection para-
digm (Blumenfeld et al. 2010). Up to 40 U of additional 
OnabotulinumtoxinA could have been administered 
at the physician’s discretion using a “follow the pain” 
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strategy into 8 additional injection sites across three head 
and neck muscles (temporalis, occipitalis, and/or trape-
zius muscles) in the PREEMPT study (Blumenfeld et al. 
2010), but we did not administer the additional dose.
Headache days, migraine days, and acute pain medica-
tion intake were used as efficacy measures. Baseline data 
were collected from patients headache diary referred 
to the previous month before starting Onabotulinum-
toxinA, and patients were evaluated every 3  months at 
the time of each injection. Every 6 months patients were 
asked to fill the Headache Impact Test (HIT)-6, used as 
a measure of efficacy as well, and the results were com-
pared with the baseline score. During the 24 months all 
adverse events (AEs), related to the drug, were registered 
and used as a safety measure.
Statistical analysis
Continuous variables are reported as mean  ±  stand-
ard deviation, rates and categorical values are reported 
as subjects-counts and percentage. A paired t Test was 
used to compare the mean headache days, migraine days, 
medication intake days and HIT-6 score at baseline and 
at each cycle of injections after Hartley’s ƒ-Max test to 
ass equal variance of data. A Chi square test was used to 
compare categorical variables.
Results
Demographic and baseline headache characteristics
The initial included population was of 155 patients 
but only 132 patients completed the 2  years follow-up. 
Table 1 shows the reasons for OnabotulinumtoxinA dis-
continuation before 24 months.
Demographic and baseline headache characteris-
tics of the 132 patients who completed the protocol are 
reported in Table 2.
The majority of patients were female (81.8  %), with 
a mean age of 43.2  years (range 18–76). The average 
time from CM onset was 10.2 years (range 1–40 years). 
All patients overused acute pain medications during 
the previous month before starting Onabotulinum-
toxinA treatment (baseline). Medication overuse was 
defined as simple analgesics intake for ≥15 days, or other 
medication classes or combination of multiple drug 
classes for ≥10 days, taken at least 2 days/week or more. 
The 93.9  % of patients had a severe (≥60) HIT-6 score 
(Table 2).
Efficacy
A comparison of all pre- and post-treatment outcomes 
is shown in Figs. 1, 2, 3, 4 and detailed data are given in 
Additional file 1: Tables S1–S5.
The headache days per month decreased significantly 
during the period of treatment from the first to the 
eighth session of therapy (pre 22.3 ± 4.1, post 7.3 ± 2.1; 
p < 0.001) (Fig. 1).
There was also a significant reduction of the migraine 
days per month during the period of treatment from the 
first to the eighth session of therapy (pre 21.4 ± 4.3, post 
6.8 ± 2.3; p < 0.001) (Fig. 2).
Accordingly, also medication intake days decreased 
significantly during the period of treatment from the 
first to the eighth session of therapy (pre 20.8 ± 4.5, post 
5.3 ± 1.7; p < 0.001) (Fig. 3).
The mean HIT-6 score decreased significantly during 
the period of treatment from the first to the last injec-
tion (pre 69.4 ± 4.9, post 52 ± 5.6; p < 0.001) (Fig. 4) and 
the proportion of patients with severe (≥60) HIT-6 score 
decreased as well (pre 93.9 %, post 22 %). After 2 years of 
treatment the mean HIT-6 score was ≤55 (some impact, 
little or no impact) in 68.2  % of patients and  ≤49 (lit-
tle or no impact) in 40.9 % of patients (data not shown). 
Notably, all the efficacy measures showed a progressive 
decline over the 2-year follow-up, with significant reduc-
tions at each time point calculated only versus baseline 
measures. Notably, after the 4th injection (12  months), 
the extent of decreases of the mean headache, migraine 
and pain medication intake days appears to be less prom-
inent than within the first 12 months of treatment.
Table 1 Reasons for OnabotulinumtoxinA discontinuation 
before 24 months
AEs adverse events
Total N = 23 (14.8 %)
OnabotulinumtoxinA indepent AEs 5 (3.2 %)
Not effective 8 (5.2 %)
Pregnancy 2 (1.3 %)
Drop out 3 (1.8 %)
Personal reasons 5 (3.2 %)
Table 2 Baseline demographics and characteristics
Data are presented as mean ± standard deviation; HIT headache impact test, 
HIT-6 Scores of 36–49 indicate little or no impact; 50–55, some impact; 56–59, 
substantial impact; ≥60, severe impact
Baseline data refers to the previous month before starting OnabotulinumtoxinA
OnabotulinumtoxinA 
155 U (n = 132)
Mean age, years 43.2 ± 13.5 (18–76)
Female,  % (n) 81.8 (108)
Diagnosis of chronic migraine, years 7.6 ± 4.3 (0.5–10)
Mean years since onset of chronic migraine 10.2 ± 4.8 (1–40)
Headache days 22.3 ± 4.1
Migraine days 21.4 ± 4.3
Pain medication intake days 20.8 ± 4.5
HIT-6 score 68.9 ± 4.3
Patients with severe HIT-6 score, % (n) 93.9 (124)
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Fig. 1 Mean change from baseline in frequency of headache days. *p < 0.001
Fig. 2 Mean change from baseline in frequency of migraine days. *p < 0.001
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Fig. 3 Mean change from baseline in monthly pain medication intake days. *p < 0.001
Fig. 4 Mean change from baseline in total HIT-6 score. *p < 0.001
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Safety and tolerability
No severe treatment-related AEs were observed (Table 3). 
Severity of the AEs was mild to moderate and was not 
a reason to interrupt OnabotulinumtoxinA injections 
in any case. All the AEs lasted for less than a week (e.g. 
headache, injection-site pain) to a maximum of 2 months 
(e.g. eyelid ptosis, musculoskeletal weakness).
Neck pain and musculoskeletal stiffness occurred 
in >75 % of the cases during the first three cycles of injec-
tions. Conversely, other AEs, as eyelid ptosis, injection-
site pain and headache did not show any correlation with 
the treatment cycle (data not shown).
Discussion
For decades several classes of drugs have been used for 
the prevention of primary chronic headaches showing 
different levels of efficacy and safety. Considering the 
large number of molecules available for each class and 
their association with severe class-related contraindica-
tion, it is not surprising to note that there are no pub-
lished data comparing safety and efficacy between all 
the classes. It is worth it to remember that none of these 
drugs are currently approved for CM prophylaxis.
In 2010, on the basis of the results of PREEMPT clinical 
program, the Medicines and Healthcare Products Regu-
latory Agency (MHRA) in the UK, and later the Federal 
Drug Administration (FDA) in USA, approved Onabot-
ulinumtoxinA injection therapy for the prevention of 
headaches in adults with CM. In 2011 also the European 
Medical Agency (EMA) approved Botox® for treatment 
of CM. OnabotulinumtoxinA was the first and, so far, the 
only prophylactic treatment to receive a specific license 
for patients with CM. Recently the European Headache 
Federation proposed a consensus statement for a new 
definition of refractory CM (Martelletti et al. 2014) which 
includes also the OnabotulinumtoxinA treatment failure 
as a diagnostic criteria for the definition of refractory CM.
A comparison between our results and the PREEMPT 
pooled data might be helpful to better understand 
OnabotulinumtoxinA long-term safety and efficacy 
(Dodick et al. 2010).
The majority of baseline characteristics of our sample 
of patients were similar to the PREEMPT population: 
mean headache days (22.3 vs. 19.9), mean migraine days 
(21.4 vs. 19.1), mean HIT-6 score (69.4 vs. 65.5) and per-
cent with severe (≥60) HIT-6 score (93.9 vs. 93.5).
At the same time, our population had some important 
differences. All our patients had MOH (vs. 64.8  %) and 
had previously failed one or more prophylaxis medica-
tions (38 % in PREMPT had never received a preventive 
treatment). Therefore, we might assume that our sam-
ple of patients had a more severe CM. Nevertheless, we 
report a similar OnabotulinumtoxinA efficacy compared 
to PREEMPT study, at least in the first year of treatment 
(the PREEMPT study considered only a 1 year follow-up).
To date, similar efficacy is indicated by the similar out-
come measures reduction at PREEMPT 24  weeks and 
our 6  months: mean headache days reduction (−8.4 vs. 
−9.4), mean migraine days reduction (−8.2 vs. −8.4), 
mean acute pain medication intake reduction (−10.1 vs. 
−9), mean HIT-6 score reduction (−4.8 vs. −5.1), pro-
portion of patients with severe (≥60) HIT-6 score (67.6 
vs. 77.3  %). Moreover, we can also compare outcome 
measures reduction at PREEMPT 56  weeks and our 
at 15  months: mean headache days frequency reduc-
tion (−11.7 vs. −13.2), mean migraine days frequency 
reduction (−11.2 vs. −13.1), mean reduction in acute 
pain medication intakes (−15.4 vs. −12.6), mean HIT-6 
score (−7.7 vs. −10.9), proportion of patients with severe 
(≥60) HIT-6 score (50.6 vs. 44.7 %).
The safety and tolerability profile that emerged from 
our study seems to be better than that of pooled data 
from PREEMPT (total treatment-related AEs: 17.5 vs. 
29.4 %).
In our Headache Clinic, the rate of patients discontinu-
ing the therapy for AEs related to OnabotulinumtoxinA 
was around the 3 %, mostly represented by women that 
experienced neck muscle weakness and eyelid ptosis.
In other real-life studies, in order to prevent the re-
occurrence of the local toxin AEs the interested injection 
sites were avoided or the dose was incorrectly reduced 
to the half (Cernuda-Morollón et  al. 2015). We do not 
feel to recommend this kind of behavior since most of 
the local AEs can be successfully avoided by improving 
the injection practice. Moreover, the preventive effect 
of OnabotulinumtoxinA seems to be dose dependent, 
therefore avoiding sites of injections or reducing the dose 
per site can be counterproductive.
The overall OnabotulinumtoxinA efficacy in reducing 
headache and migraine days, and therefore the pain med-
ication use and overuse without any relevant and severe 
side effect is of central importance also for reducing CM 
associated disability, increasing patients quality of life 
and reducing health resource utilization. Furthermore, 
Table 3 Summary of  the overall treatment-related AEs 
reported in 24 months
AEs adverse events
Adverse event observed Number of patients/132 (%)
Total treatment-related AEs 23 (17.5)
Injection-site pain 4 (3.3)
Neck pain 5 (3.8)
Musculoskeletal weakness 5 (3.8)
Eyelid ptosis 4 (2.9)
Headache 5 (3.7)
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reducing the attacks frequency and the pain medication 
use and abuse might be also an essential part of the car-
diovascular risk reduction in patients affected with CM 
(Tana et al. 2013).
A particularly interesting finding of this study is the 
progressive improvement in all measures during the 
2  years of follow-up. Although the extent of the head-
ache, migraine and medication intake days reduction 
tends to be less prominent after the 4th injection, this 
data demonstrate that OnabotulinumtoxinA efficacy is at 
least maintained and possibly continues to improve over 
time.
The results of other studies in a real-life setting have 
been recently published and confirm the efficacy and 
safety of OnabotulinumtoxinA, even if differences in 
some important features between the studies should 
be underlined. Pedraza et  al. (2015) evaluated fifty-two 
patients treated with one injection of 155 U, with only 39 
receiving a second treatment; 82.7 % of them presented 
MOH, and the use of preventive therapy during the study 
was allowed. Grazzi and Usai (2015) evaluated forty-six 
patients treated with 3 injections sessions and 20 patients 
treated with 5 injections; all of them received the dosage 
of 155 U for each session and they were all suffering from 
CM with MOH. Notably, it was not mentioned if other 
preventive therapies were allowed.
Khalil et  al. (2014) showed that OnabotulinumtoxinA 
155 U reduced the number of headache and migraine 
days in a prospective study of 254 adults with CM, and 
increased the number of headache-free days only for the 
first month after treatment. Cernuda-Morollón et  al. 
(2015) reported their experience in a sample of 132 CM 
patients treated with OnabotulinumtoxinA 155–195 U 
following the PREEMPT protocol. They showed a long-
term efficacy to OnabotulinumtoxinA injections after 
1 year in about three quarters of the patients. The same 
efficacy was maintained in all the 20 patients that were 
still treated after 4 years. However, in the paper there is 
no mention about the dosage (155 or 195 U).
Our study has two major points of strength. First, the 
same physician that had received a proper training as 
injector was the same that followed each patient up over 
the 2 years. This might have contributed in reducing the 
variation in the injection sites, possibly linked to the dif-
ferent operators performing the ptotocol. Therefore, the 
importance of a proper training offered to each physician 
approaching to this injective therapy might be central for 
OnabotulinumtoxinA treatment (Blumenfeld et al. 2010). 
Second, we evaluated a single dosage (155 U) in a large 
population for a relatively long period (8 treatments in 
2 years).
Limitations of our study are also noteworthy. The 
first limitation is the absence of a control group; the 
second is the lack of collected descriptive data for some 
of the outcomes (e.g. headache and migraine episodes, 
moderate/severe headache days, Migraine-Specific 
Quality of Life questionnaire). The choice to not collect 
excessive descriptive data has been made to increase 
the compliance of our patients in fulfilling the diaries. 
In fact, usually patients report in diaries only infor-
mation related to headache days, migraine days, day 
of utilization of drug and any adverse event. Similarly, 
the primary end point of the pooled data of PREEMPT 
was the frequency of headache days, which is consid-
ered more sensitive than headache episodes and fulfills 
recently proposed clinical trial guidelines for evalu-
ating headache prophylaxis in CM (Silberstein et  al. 
2008). Another limitation is the absence of data about 
the length of time of effectiveness of treatment within 
the 3 months: in fact, we calculated the headache days, 
migraine days, and medication intake days as a mean 
of the overall days reported by the patients in the pre-
vious 3 months, without considering single months or 
weeks as outcome measures. This implies that patients 
experiencing variations in the OnabotulinumtoxinA 
length of action within the 3 months might have been 
not recognized.
The last criticism about this study could be repre-
sented by the selection of the population. We decided to 
prospectively treat and evaluate only patients with CM 
and coexisting MOH, which precluded the diagnosis 
of CM according to the ICHD-II (Headache Classifica-
tion Subcommittee 2004; Headache Classification Com-
mittee 2006). The PREEMPT studies received the same 
critics. MOH constitutes a plus of CM and it is hard 
to think about its appearance not being related to CM 
itself, unless patients attempt counterproductive stoi-
cism. Since MOH does not stand alone, it is our opin-
ion that it should be at least considered a complication 
of CM and not just a simple form of secondary headache 
(Negro and Martelletti 2011). Accordingly prospective 
data in real-life clinical practice from the Hull Migraine 
Clinic shows no difference in the therapeutic outcome in 
patients with or without analgesic overuse (Ahmed et al. 
2015).
Conclusions
Our data from a real-life setting confirm Onabotulinum-
toxinA efficacy and safety evidence from previous RCT 
studies.
OnabotulinumtoxinA proved to have indisputable 
advantages over other drugs used for decades for CM 
prophilaxys: higher efficacy and tolerability, that are 
maintained even after a long period of treatment. In our 
opinion, OnabotulinumtoxinA should be considered the 
gold standard preventive therapy for CM.
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